Curis Inc to Discuss Updated Clinical Data for CA-4948 in AML/MDS Presented at EHA Virtual Congress Transcript
Good morning and welcome to Curis' virtual KOL event, discussing updated data for CA-4948 in AML/MDS, presented at EHA. (Operator Instructions) Please note, this event is being recorded. I would now like to turn the conference call over to Curis' Chief Financial Officer, Bill Steinkrauss. Please go ahead.
Thank you, and welcome to Curis' KOL event to discuss the updated clinical data from the Phase I/II study of CA-4948 in AML and MDS, as presented at the European Hematology Association's 2021 Virtual Congress today.
Before we begin, I would like to remind everyone to go to the Investors section of our website at www.curis.com to find our data release and the slides from this presentation. I would also like to remind everyone that during the call, we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties and actual results may differ
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |